Skip to content

Engaging the Experts – A New Landscape: Biosimilars in Multiple Sclerosis

A New Landscape: Biosimilars in Autoimmune Indications

Accelerating Biosimilar Adoption: Conversation with the Experts

Checklists for workflow considerations relating to adalimumab biosimilars

The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Era of biosimilars in rheumatology: reshaping the healthcare environment

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

A place for biosimilars in the changing multiple sclerosis treatment